Viz.ai, a frontrunner in artificial intelligence (AI) powered disease detection and intelligent care coordination, has inked an exclusive agreement with the University of California, San Francisco (UCSF) to commercialize three AI algorithms. Developed by leading researchers at UCSF, these algorithms aim for the automated detection of cardiovascular diseases, including cardiac amyloidosis, pulmonary hypertension, and supraventricular tachycardia. They rely on electrocardiograms (ECGs), the diagnostic gold standard for assessing cardiac structure and heart electrical activity.

AI Algorithms Meet Clinically Accepted Standards, Boost Care

Anthony Francis, executive director of the Office of Technology Management and Advancement at UCSF, expressed optimism about the algorithms’ clinical applications. “These AI-powered algorithms improve on existing systems and meet or exceed clinically accepted standards of care,” said Francis. Viz.ai’s platform specializes in using AI to auto-detect a range of suspected cardiovascular diseases with regulatory-cleared algorithms and supports HIPAA-compliant communication tools for care coordination.

Addressing a Global Health Crisis

Cardiovascular disease remains the leading cause of death globally, claiming over 18 million lives annually. Viz.ai’s focus on AI-powered early detection is critical for tackling this healthcare challenge. Upon receiving regulatory clearance, the newly-developed algorithms will augment Viz.ai’s existing suite of offerings, which include ECG-based AI algorithms, an ECG viewer, and AI-interpretation of echocardiograms.

Aiming for Early Detection in Millions of Cases

Steve Sweeny, vice president of life science business development and strategy at Viz.ai, highlighted the real-world impact of the partnership. “Cardiac amyloidosis, pulmonary hypertension, and supraventricular tachycardia affect up to 75 million people worldwide and can take years to diagnose,” said Sweeny. He emphasized the algorithms’ role in facilitating earlier cardiovascular disease detection, improving patient outcomes, increasing access to life-saving treatments, and reducing healthcare provider burnout.

With this groundbreaking partnership, Viz.ai and UCSF aim to revolutionize the early detection of cardiovascular diseases, bringing intelligent care coordination to the forefront of a global health crisis.

  Anthony Francis, Cardiovascular disease, pulmonary hypertension, Steve Sweeny, Tachycardia, UCSF, University of California, USA, ventricular tachycardia, Viz.ai